Glofitamab for Relapsed or Refractory Diffuse Large B-Cell Lymphoma.
Michael J DickinsonCarmello Carlo-StellaFranck MorschhauserEmmanuel BachyPaolo CorradiniGloria IacoboniCyrus KhanTomasz WróbelFritz OffnerMarek TrněnýShang-Ju WuGuillaume CartronMark HertzbergAnna SuredaDavid Perez-CallejoLinda LundbergJames RelfMark DixonEmma ClarkKathryn HumphreyMartin HutchingsPublished in: The New England journal of medicine (2022)
Glofitamab therapy was effective for DLBCL. More than half the patients had an adverse event of grade 3 or 4. (Funded by F. Hoffmann-La Roche; ClinicalTrials.gov number, NCT03075696.).